Actively Recruiting

Phase 3
Age: 18Years - 85Years
All Genders
NCT07505004

Double-blind, Randomized Clinical Trial Evaluating the Efficacy and Safety of Vormatrigine in Adults With Focal Seizures

Led by Praxis Precision Medicines · Updated on 2026-04-01

300

Participants Needed

7

Research Sites

65 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

A multicenter, double-blind, randomized, placebo-controlled clinical trial to evaluate the efficacy and safety of vormatrigine in adults with focal seizures (POWER2)

CONDITIONS

Official Title

Double-blind, Randomized Clinical Trial Evaluating the Efficacy and Safety of Vormatrigine in Adults With Focal Seizures

Who Can Participate

Age: 18Years - 85Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Diagnosis of focal onset epilepsy according to the International League Against Epilepsy Classification (2017)
  • Brain CT or MRI ruling out progressive causes of epilepsy prior to randomization
  • Taking stable doses of 1 to 3 acceptable anti-seizure medications for at least 4 weeks before screening
  • At least 4 countable focal seizures during the 4 weeks before randomization with no more than 21 seizure-free days
  • Seizure diary completed for at least 80% of days during the observation period
Not Eligible

You will not qualify if you...

  • History within 12 months of pseudo or psychogenic seizures, cluster seizures that cannot be counted, convulsive status epilepticus requiring hospitalization and intubation, or seizures due to illicit drug or alcohol use
  • Seizures caused by ongoing infection, neoplasia, demyelinating disease, progressive degenerative disease, metabolic illness, progressive structural lesion, or encephalopathy
  • EEG showing patterns inconsistent with focal seizures
  • Planned epilepsy surgery during the trial
  • Neurosurgery for seizures less than 1 year before enrollment
  • Radiosurgery less than 2 years before enrollment
  • Neurostimulator placed less than 1 year before screening or unstable settings if placed more than 1 year prior
  • Active suicidal plan or intent in past 6 months, or history of suicide attempt in past 2 years or multiple lifetime attempts
  • Significant ongoing disease, laboratory abnormalities, substance abuse, psychiatric, medical, or surgical conditions
  • History of malignancy, myeloproliferative or lymphoproliferative disorders within past 3 years
  • Uncontrolled cardiac diseases including conduction and structural abnormalities
  • Elevated total bilirubin (>1.5 times upper limit normal), ALT or AST (>3 times upper limit normal)
  • HIV infection or positive HIV screening, active hepatitis B or C infection
  • Use of any experimental drug, device, gene or cell therapy within 30 days or 5 half-lives prior to screening
  • Use of vigabatrin in last 5 years without stable visual field testing
  • Felbamate use must be stable for at least 2 years or discontinued 2 months prior to screening
  • Significant allergic reaction to an anti-seizure medication including severe dermatological, hematological, or organ toxicity reactions
  • Pregnant, breastfeeding, positive pregnancy test at screening, or planning pregnancy during the study
  • Previous exposure or known hypersensitivity to vormatrigine or its components

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 7 locations

1

Praxis Research Site

Miami, Florida, United States, 33133

Actively Recruiting

2

Praxis Research Site

Miami Lakes, Florida, United States, 33016

Actively Recruiting

3

Praxis Research Site

Naples, Florida, United States, 34116

Not Yet Recruiting

4

Praxis Research Site

Marlboro, New Jersey, United States, 07746

Actively Recruiting

5

Praxis Research Site

Niagara Falls, New York, United States, 14304

Actively Recruiting

6

Praxis Research Site

Raleigh, North Carolina, United States, 27607

Actively Recruiting

7

Praxis Research Site

Houston, Texas, United States, 77058

Actively Recruiting

Loading map...

Research Team

S

Senior Medical Director Clinical Development

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

QUADRUPLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

4

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Double-blind, Randomized Clinical Trial Evaluating the Efficacy and Safety of Vormatrigine in Adults With Focal Seizures | DecenTrialz